Effects of 12 mg vs. 6 mg dexamethasone on thromboembolism and bleeding in patients with critical COVID-19 - a post hoc analysis of the randomized, blinded COVID STEROID 2 trial.

Sandra JonmarkerFelix AlarcónJacob LitorellAnders GranholmEva Joelsson AlmMichelle ChewLene RussellSarah WeiheEmilie Kabel MadsenNick MeierJens Wolfgang LeistnerJohan MårtenssonJacob HollenbergAnders PernerMaj-Brit Nørregaard KjærMarie Warrer MunchMartin DahlbergMaria CronhjortRebecka Rubenson Wahlin

Published in: Annals of intensive care (2023)

Among patients with critical COVID-19, 12 mg vs. 6 mg dexamethasone daily did not result in a statistically significant difference in the composite outcome of death or thromboembolism. However, uncertainty remains due to the limited number of patients.

Keyphrases

coronavirus disease
sars cov
end stage renal disease
phase iii
low dose
phase ii
placebo controlled
chronic kidney disease
study protocol
newly diagnosed
high dose
ejection fraction
open label
double blind
clinical trial
peritoneal dialysis
atrial fibrillation